ROCHE REMAINS A BELLWETHER, DESPITE RECENT (R&D) JITTERS (ADD; 14% UPSIDE)
-" Since early 2022, an already fragile global economy (surfing on monetary excesses) has faced several challenges – spiralling inflation and supply-chain disruptions – due to the war in Europe, ..."
You may also be interested by these reports :
Reality digested – Looking ahead
Novavax and Siegfried extend aseptic fill & finish collaboration for Novavax’s protein-based coronavirus vaccine Nuvaxovid
Novartis again shared a reassuring outlook, with promising sales growth and margin expansion targets. The only difference now is that the firm has ...
11th Baader Investment Conference: Positive outlook for the mid-/long-term